Program
cagrilintide
Also written as “Cagrilintide”, “NNC0174-0833” and “CagriSema”.
In Novo Nordisk’s own words, CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide and a GLP-1 receptor agonist, semaglutide.
. Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Hypertension · Renal Insufficiency, Chronic · Cardiovascular Diseases, led by Novo Nordisk.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 5018 open or running | phase 3since May 24, 2022 | Nov 21, 2014 | Mar 1, 2027phase 3 · NCT07011667 |
- Named in Novo Nordisk’s own pipeline as
Cagrilintide
, phase 3, as of Nov 5, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 32 earlier studies, Nov 21, 2014 to Jan 27, 2025.
- Jun 9, 2020Named cagrilintideINNProposed as its International Nonproprietary Name in WHO's List 123 · before, NNC0174-0833
- May 30, 2025Phase 1 study in ObesityNCT07010432 · 144 planned · Denmark
- Jun 1, 2025Phase 3 study in ObesityNCT07011667 · 609 enrolled · United States
- Sep 13, 2025Phase 1 study in ObesityNCT07184086 · 80 enrolled · United States
- Oct 23, 20252 phase 3 studiesNCT07220759, NCT07220642
- Nov 19, 2025Phase 3 study in OverweightNCT07253285 · 460 planned · United States, Australia, Austria and more
- Dec 5, 2025Phase 3 study in Diabetes Mellitus, Type 2NCT07282613 · 80 planned · United States, Argentina, Brazil and more
- Jan 21, 2026Phase 3 study in OverweightNCT07357766 · United States, Bulgaria, Denmark and more
- Jan 21, 2026Phase 2 study in Diabetes Mellitus, Type 2NCT07357740 · United States, Denmark, Greece and more
- Apr 7, 20263 phase 1 studiesNCT07527195, NCT07597018, NCT07557953
- Apr 27, 2026Phase 3 study in ObesityNCT07564414 · 2,500 planned · United States, Argentina, Australia and more
- May 17, 20262 phase 1 studiesNCT07605052, NCT07607587
- Jul 30, 2026Phase 3 study in OverweightNCT07745504 · 285 planned · United States, Greece, Hungary and more
- Sep 8, 2026Phase 3 study in Diabetes Mellitus, Type 2NCT07817251 · 210 planned · United States
- Oct 30, 2026Phase 3 study in HypertensionNCT07919405 · 1,408 planned · United States, Argentina, Australia and more
Ahead
- Mar 1, 2027Primary completion: phase 3 study in ObesityNCT07011667
- Apr 13, 2027Primary completion: phase 1 study in OverweightNCT07557953
- May 11, 2027Primary completion: phase 3 study in ObesityNCT07220642
- May 12, 2027Primary completion: phase 3 study in OverweightNCT07220759
TargetBeta
“CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide and a GLP-1 receptor agonist, semaglutide.”company, read by Claude · source
Other programs on CALCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zenagamtide | Novo Nordisk | phase 3 | 36 |
| eloralintide | Eli Lilly | phase 3 | 26 |
| petrelintiderule | Zealand Pharma | phase 3 | 11 |
| ABBV-295 | AbbVie | phase 2 | 5 |
| PF-08653945 | Pfizer | phase 2 | 2 |
| GUB014295 | AbbVie | phase 1 | 1 |
| CagriSema A | Novo Nordisk | phase 1 | 1 |
Studies
All 50 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07919405Hypertension · United States, Argentina, Australia and more | 3 | Not yet recruiting | Jun 1, 2028 | 1,408 |
| NCT07817251Diabetes Mellitus, Type 2 · United States | 3 | Recruiting | Jun 9, 2027 | 210 |
| NCT07745504Overweight · United States, Greece, Hungary and more | 3 | Recruiting | May 18, 2027 | 285 |
| NCT07607587Obesity · United States | 1 | Recruiting | Nov 19, 2027 | 114 |
| NCT07605052Overweight · United States | 1 | Completed | Aug 19, 2026 | 50 |
| NCT07564414Obesity · United States, Argentina, Australia and more | 3 | Recruiting | Feb 23, 2028 | 2,500 |
| NCT07557953Overweight · Germany | 1 | Recruiting | Apr 13, 2027 | 120 |
| NCT07597018Obesity · Germany | 1 | Recruiting | May 28, 2027 | 234 |
| NCT07527195Obesity · Denmark | 1 | Recruiting | Apr 28, 2028 | 100 |
| NCT07357766Overweight · United States, Bulgaria, Denmark and more | 3 | Withdrawn | Nov 29, 2027 | 0 |
| NCT07357740Diabetes Mellitus, Type 2 · United States, Denmark, Greece and more | 2 | Withdrawn | Aug 25, 2027 | 0 |
| NCT07282613Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Recruiting | Sep 7, 2029 | 80 |
| NCT07253285Overweight · United States, Australia, Austria and more | 3 | Recruiting | Mar 20, 2030 | 460 |
| NCT07220759Overweight · United States, Argentina, Canada and more | 3 | Active, not recruiting | May 12, 2027 | 330 |
| NCT07220642Obesity · United States, Argentina, Australia and more | 3 | Active, not recruiting | May 11, 2027 | 300 |
| NCT07184086Obesity · United States | 1 | Active, not recruiting | Oct 12, 2027 | 80 |
| NCT07011667Obesity · United States | 3 | Active, not recruiting | Mar 1, 2027 | 609 |
| NCT07010432Obesity · Denmark | 1 | Recruiting | May 3, 2028 | 144 |
| NCT06797869Diabetes Mellitus, Type 2 · United States, Canada, Denmark and more | 2 | Completed | Jun 26, 2026 | 142 |
| NCT06780449Obesity · United States, Belgium, Canada and more | 3 | Active, not recruiting | Aug 28, 2028 | 400 |
| NCT06716307Obesity · United States | 1 | Completed | Mar 28, 2025 | 18 |
| NCT06534411Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | Jun 2, 2026 | 1,023 |
| NCT06409130Alcohol-related Liver Disease · United States, Australia, Bulgaria and more | 2 | Completed | Nov 21, 2025 | 270 |
| NCT06403761Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Dec 28, 2025 | 158 |
| NCT06388187Obesity · United States, Canada, France and more | 3 | Completed | Apr 22, 2026 | 300 |
| NCT06323174Diabetes Mellitus, Type 2 · United States, China, Hungary and more | 3 | Completed | Oct 1, 2025 | 189 |
| NCT06323161Diabetes Mellitus, Type 2 · United States, China, Japan and more | 3 | Completed | Sep 9, 2025 | 274 |
| NCT06289504Obesity · Canada | 1 | Completed | Oct 16, 2024 | 34 |
| NCT06267092Overweight · Germany | 1 | Completed | Apr 7, 2025 | 164 |
| NCT06221969Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | Mar 4, 2026 | 1,024 |
| NCT06207877Obesity · Germany | 1 | Completed | Oct 16, 2024 | 62 |
| NCT06131437Obesity · United States | 3 | Completed | Dec 8, 2025 | 809 |
| NCT06131372Renal Insufficiency, Chronic · United States, Argentina, Brazil and more | 2 | Completed | Sep 24, 2025 | 626 |
| NCT06065540Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | Nov 19, 2025 | 2,734 |
| NCT05996848Obesity · China | 3 | Completed | Jan 6, 2025 | 300 |
| NCT05813925Obesity · Japan, Taiwan | 3 | Completed | Jan 17, 2025 | 331 |
| NCT05804162Obesity · Germany | 1 | Completed | Aug 12, 2023 | 107 |
| NCT05669755Cardiovascular Diseases · United States, Argentina, Australia and more | 3 | Active, not recruiting | Sep 1, 2027 | 7,101 |
| NCT05567796Obesity · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 30, 2024 | 3,400 |
| NCT05564104Hepatic Impairment · Czechia, Germany, Slovakia | 1 | Completed | Sep 6, 2024 | 32 |
| NCT05394519Overweight · United States, Austria, Canada and more | 3 | Completed | Jan 28, 2025 | 1,200 |
| NCT04982575Diabetes Mellitus, Type 2 · United States | 2 | Completed | Jul 7, 2022 | 92 |
| NCT04940078Obesity · Canada, Denmark | 1 | Completed | Jan 19, 2022 | 40 |
| NCT04209049Overweight · United States | 1 | Completed | Jan 5, 2021 | 33 |
| NCT04074174Overweight · Canada | 1 | Completed | Mar 6, 2020 | 31 |
| NCT03856047Overweight · United States, Canada, Denmark and more | 2 | Completed | Mar 2, 2020 | 706 |
| NCT03787225Obesity · United States | 1 | Completed | Jun 4, 2019 | 66 |
| NCT03600480Obesity · United States | 1 | Completed | Jun 12, 2020 | 96 |
| NCT02958085Nutrition Disorders · United States | 1 | Completed | Jan 24, 2018 | 96 |
| NCT02300844Nutrition Disorders · United States | 1 | Completed | Mar 21, 2016 | 54 |
How it is read
Names in the registry
- “Cagrilintide”, 29 entries
- “NNC0174-0833”, 7 entries
- “CagriSema”, 3 entries
- “CagriSema (Cagrilintide B and Semaglutide I)”, 3 entries
- “Cagrisema”, 2 entries
Conditions, from the studies’ own filings
- Obesity, 34 studies
- Diabetes Mellitus, Type 2, 11 studies
- Hypertension, 1 study
- Renal Insufficiency, Chronic, 1 study
- Cardiovascular Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.